By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Innovator’s Pitch Challenge (IPC) returned to RESI San Diego 2026, bringing together some of the most promising early-stage life science companies for one of the conference’s signature events. Designed to connect early-stage innovators with active investors and strategic partners, the IPC provides a platform for companies to showcase breakthrough technologies while gaining valuable exposure and feedback.
Each finalist delivered a six-minute presentation followed by a live Q&A with an investor judging panel. Throughout the conference, participants also met with investors during one-on-one partnering meetings and networking sessions, extending conversations well beyond the pitch stage.
The IPC winners are determined through a combination of investor judge evaluations and RESI Cash voting. Judges evaluate each company based on the strength of its technology, investment opportunity, presentation, and responses during Q&A, while attendees allocate RESI Cash to the companies they believe demonstrate the greatest investment potential. Together, these scores recognize companies that impressed both the judging panel and the broader RESI community.
Congratulations to the overall winners of the RESI San Diego 2026 Innovator’s Pitch Challenge:
1st Place: Nanotrace
Nanotrace combined the best attributes of chemotherapy, nanoparticle delivery mechanisms, and the latest advancements in gene therapeutics to build a revolutionary oncology platform. Based on our team’s decades of research in these fields, and the maturation of nanomedicine, our product is a novel targeting platform which recognizes cancer cells by its very blueprint – gene expression. In part by using AI, that highly specific recognition is programmed to release a chemotherapeutic payload inside a cancer cell while leaving healthy cells unaffected. Our platform will transform how we treat not only cancer but a whole spectrum of genetic disorders. Nanotrace is founded by Dr. Will Briley, PhD Molecular Biology from Northwestern; Dr. Paul Weiss, renowned nanoscientist, distinguished UCLA professor, and a UC Presidential Chair; David Spector, an experienced founder and formerly of Sequoia Capital, Google, and MIT; and, Chief Medical Advisor, Dr. Krishna Komanduri, Department Chief & Head of Hematology & Oncology, UCSF.
2nd Place: Pinion Immunotherapeutics
Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8⁺ T cells while inducing virus-neutralizing antibodies to achieve durable immune control. Pinion operates as a lean, high-impact virtual company, deploying capital directly to science and clinical trials, not overhead. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology. Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.
3rd Place: FELIQS
Feliqs is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options. Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.
In addition to the overall winners, several companies earned the highest combined judge and RESI Cash scores within their individual pitch sessions. Congratulations to these outstanding innovators for delivering exceptional presentations and capturing investor interest throughout the competition.
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Every company that participated in the Innovator’s Pitch Challenge demonstrated the innovation, passion, and entrepreneurial spirit that continue to define the RESI community. Congratulations to all of this year’s participants.
Will Your Company Be Next?
Applications are now open for the RESI Boston Innovator’s Pitch Challenge, taking place during the expanded two-day, in-person RESI Boston conference this September during Biotech Week Boston.
The IPC is more than a pitch competition. It is an opportunity to present your company to active investors, receive expert feedback, gain additional visibility through poster presentations and partnering meetings, and compete for recognition among the global life science investment community.
Whether you’re preparing for your next financing round or looking to build strategic partnerships, the Innovator’s Pitch Challenge can help elevate your fundraising efforts.
Applications are now open. Apply today and take the stage at RESI Boston.
| Apply to Pitch at RESI Boston |
Next Phase Newsletter 